| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 830.31 | 805.97 | 741.29 | 733.67 |
yoy growth (%) | 3.02 | 8.72 | 1.03 | 8.56 |
Raw materials | -256.59 | -265.56 | -351.75 | -368.79 |
As % of sales | 30.9 | 32.95 | 47.45 | 50.26 |
Employee costs | -175.62 | -149.27 | -113.08 | -91.52 |
As % of sales | 21.15 | 18.52 | 15.25 | 12.47 |
Other costs | -171.09 | -146.21 | -97.39 | -90.7 |
As % of sales (Other Cost) | 20.6 | 18.14 | 13.13 | 12.36 |
Operating profit | 227 | 244.9 | 179.06 | 182.64 |
OPM | 27.33 | 30.38 | 24.15 | 24.89 |
Depreciation | -40.84 | -34.95 | -32.77 | -26.65 |
Interest expense | -17.46 | -4.32 | -2.12 | -2.79 |
Other income | 33.9 | 11.26 | 23.31 | 19.88 |
Profit before tax | 202.59 | 216.88 | 167.48 | 173.07 |
Taxes | -71.14 | -44.14 | -34.24 | -41.08 |
Tax rate | -35.11 | -20.35 | -20.44 | -23.73 |
Minorities and other | 0 | 25.52 | 0 | 0 |
Adj. profit | 131.44 | 198.26 | 133.23 | 131.98 |
Exceptional items | 52.94 | -4.54 | 0 | -4.54 |
Net profit | 184.39 | 193.71 | 133.23 | 127.44 |
yoy growth (%) | -4.81 | 45.39 | 4.54 | 12.92 |
NPM | 22.2 | 24.03 | 17.97 | 17.37 |
It targets to initiate first-in-human clinical trials in patients with Essential Thrombocythemia and Polycythemia Vera.
Here are some of the stocks that may see significant price movement today: Larsen & Toubro, Lodha Developers, Shilpa Medicare, etc.
USFDA conducted the Good Manufacturing Practices (GMP) inspection from October 24 to October 30 in 2024.
The certification came after a successful inspection by the Finnish Medicines Agency on behalf of EMA from March 10 to March 14, 2025
The partnership will work on a new biological entity (NBE) in the immuno-oncology field to better treat cancer.
Here are some of the stocks that may see significant price movement today: Aditya Birla Real Estate, Shilpa Medicare, Swiggy, etc.
No regulatory issues were raised by the USFDA at Unit-2 during the inspection, the company said in a regulatory filing.
Shilpa Medicare said it has completed Phase 3 trials for SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets in 165 NAFLD patients in India.
The certification followed a successful inspection by the European Medicines Agency, Austria, held from September 24 to September 26 at the Nacharam, Hyderabad facility.
This FDA approval is a milestone in cancer therapy as it presents a more convenient and precise alternative to the traditional tablet forms.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
